refludan
celgene europe ltd. - lepirudin - thromboembolism; thrombocytopenia - antithrombotic agents - anticoagulation in adult patients with heparin-induced thrombocytopenia type ii and thromboembolic disease mandating parenteral antithrombotic therapy.the diagnosis should be confirmed by the heparin-induced platelet activation assay or an equivalent test.
refludan powder for solution
bayer inc - lepirudin - powder for solution - 50mg - lepirudin 50mg - direct thrombin inhibitors
refludan
celgene australia pty ltd - lepirudin -
refludan
sanofi-aventis new zealand limited - lepirudin 50mg - powder for injection - 50 mg - active: lepirudin 50mg excipient: mannitol sodium hydroxide
refludan 50mg powder for solution for injection vials
celgene ltd - lepirudin - powder for solution for injection - 50mg
bivalirudin cipla 250 milligram pdr/conc/soln/inj/inf
cipla (eu) limited - bivalirudin - pdr/conc/soln/inj/inf - 250 milligram - direct thrombin inhibitors
angiox
the medicines company uk ltd - bivalirudin - acute coronary syndrome - antithrombotic agents - angiox is indicated as an anticoagulant in adult patients undergoing percutaneous coronary intervention (pci), including patients with st-segment-elevation myocardial infarction (stemi) undergoing primary pci.angiox is also indicated for the treatment of adult patients with unstable angina / non-st-segment-elevation myocardial infarction (ua / nstemi) planned for urgent or early intervention.angiox should be administered with aspirin and clopidogrel.
angiox 250mg powder for concentrate for solution for infusion vials
the medicines company uk ltd - bivalirudin - powder for solution for infusion - 250mg
bivalirudin 250mg powder for concentrate for solution for infusion vials
accord-uk ltd - bivalirudin - powder for solution for infusion - 250mg
angiomax
the medicines company australia pty ltd - bivalirudin -